We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

ROCHE DIAGNOSTICS CORP

Roche Diagnostics Corporation is the North American headquarters of Roche Diagnostics, a global leader in diagnostics... read more Featured Products: More products

Download Mobile App




Early Prediction of Resistance to Tyrosine Kinase Inhibitors Reported

By LabMedica International staff writers
Posted on 31 Mar 2020
Epidermal growth factor receptor (EGFR) gene mutations that confer sensitivity to tyrosine kinase inhibitors (TKI) in non-small cell lung carcinomas paved the way for a precision medicine approach in this neoplastic form. More...


At the time of clinical diagnosis, the detection of EGFR mutations in tumor tissue or circulating tumor DNA (ctDNA), when tissue is unavailable, is mandatory for the selection of patients. A limited number of studies conducted with quantitative of semi-quantitative mutation detection methods have suggested a correlation between the amount of the sensitizing EGFR mutant allele (sEGFRma) in plasma and tumor burden.

Oncology specialist at the University of Chieti (Chieti, Italy) and their colleagues tested 116 stage IIIB/IV Non-Small-Cell Lung Cancer (NSCLC) patients, carrying EGFR mutations in their tumors and treated with first/second generation anti-EGFR TKIs, for T790M mutation at clinical progression by liquid biopsy or tumor re-biopsies.

Two blood samples were obtained at each collection, subjected to plasma separation and stored at −80 °C until DNA Extraction. DNA was extracted from the plasma using the cobas cfDNA Sample Preparation kit vers.2 (Roche Molecular Systems, Pleasanton, CA, USA), and recovered in 200 μL of elution buffer. Half of the volume was immediately used for EGFR mutation assessment by the Roche cobas EGFR Mutation Test v2 assay, Polymerase chain reactions (PCR) reactions were run on the Roche cobas z 480 analyzer. An innovative massive parallel sequencing (MPS) approach (SureSelect Cancer All-In-One; Agilent Technologies, Santa Clara, California, USA) was used to optimize the management of the biological material.

The team reported that plasma analysis by the EGFR Cobas test showed in 57 (89%) cases a substantial decrease in the levels of the sensitizing EGFR mutant allele (sEGFRma), down to a non-detectable value. These patients were defined as plasmatic good responders (PGR). In seven (11%) patients, the sEGFRma did not drop to zero (plasmatic poor responders, PPR). In these latter cases, Massive Parallel Sequencing (MPS) analysis at the end of the first month and at clinical progression showed the presence of resistant-inducing mutations, including MET and HER2 gene amplification, KRAS and PIK3CA gene mutations. PPR showed disease progression in five (71%) cases, stable disease in two (29%) cases, and a shorter median Progression-free survival (PFS) (4.3 ± 1.1 months) than that observed in PGR (13.3 ± 1.2 months).

The authors concluded that their results indicate that a subset of NSCLC patients subjected to second-line treatment with osimertinib are resistant to treatment due to the presence of different types of mutations. Plasma monitoring by a simple RT-PCR-based EGFR mutation test in the first month of treatment may be useful to rapidly identify these cases and subject them to MPS analysis for further characterization and treatment. The study was published on March 17, 2020 in the journal Oncotarget.

Related Links:
University of Chieti
Roche Molecular Systems
Agilent Technologies



Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
New
Pan-Cancer Panel
TruSight Oncology 500
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.